Been off the grid for a bit, but I’m pleasantly surprised at the rise and rise of LABS as part of our portfolio. I wonder if investors would be more amenable to a CR if a) we have a CEO appointment, b) monies raised go directly into the conversion of the warrants in LABS, FAF, Weed Me, and Embark Health, in addition to the convertible notes in Weed Me?
Potential of three further listings this year is exciting, yet I’m dumbfounded by the following missing piece:
Lift your game MMJ!
Ann: MMJ NTA Backing and Portfolio Performance, page-2
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
